The Arking Lab studies the genomics of complex human disease, with the primary goal of identifying and characterizing genetics variants that modify risk for human disease. The group has pioneered the use of genome-wide association studies (GWAS), which allow for an unbiased screen of virtually all common genetic variants in the genome. The lab is currently developing improved GWAS methodology, as well as exploring the integration of additional genome level data (RNA expression, DNA methylation, protein expression) to improve the power to identify specific genetic influences of disease. The Arking Lab is actively involved in researching: • autism, a childhood neuropsychiatric disorder • cardiovascular genomics, with a focus on electrophysiology and sudden cardiac death (SCD) • electrophysiology is the study of the flow of ions in biological tissues Dan E. Arking, PhD, is an associate professor at the McKusick-Nathans Institute of Genetic Medicine and Department of Medicine, Division of Cardiology, Johns Hopkins University.

Research in the Roberto Salvatori Lab focuses on the genetic causes of isolated growth hormone deficiency (GHD), consequences of untreated GHD, and cortisol excess and deficiency. Current work explores GHD’s relation to obesity and indicates that Cushing's syndrome may be under-recognized in patients undergoing bariatric surgery. We recently took part in a retrospective, multicenter, international study to characterize a large series of pituitary gigantism patients, a condition that has not been studied previously in a standardized way.

The Advocacy and Research on Reproductive Wellness of Incarcerated People (ARRWIP) group was founded in 2017 by Dr. Carolyn Sufrin of Johns Hopkins Complex Family Planning Serivces. The goal of our research is to create opportunities to improve reproductive wellbeing for people affected by the criminal legal system – including making full-scope, compassionate reproductive health care accessible for people experiencing incarceration and advocating for alternatives to incarceration.

The Stephen Sisson Lab focuses on medical education, community outreach and ambulatory care. We recently demonstrated concurrent validity between performance on an ambulatory curriculum, the Internal Medicine In-Training Examination (IM-ITE) and the American Board of Internal Medicine Certifying Examination (ABIM-CE).

Research in the Steven Levin Lab focuses on chemical neurolysis, epiduroscopy (and training for physicians), opioid administration, and the use of alternative therapies for pain management. In collaboration with the American Society of Law, Medicine and Ethics and with funding from a Donahue Foundation Grant, we study social and ethical considerations in pain management. We have also been involved in clinical trials of novel analgesics.

Research in the Saowanee Ngamruengphong Lab focuses on methods for diagnosing and managing gastrointestinal conditions, including premalignant and malignant lesions of the gastrointestinal tract, esophageal cancer, colon polyps, and biliary and pancreatic disease. Our most recent work includes investigating a novel hybrid technique for closure of refractory gastrocutaneous fistula. We also conducted an international multicenter study that compared endoscopic ultrasound-guided pancreatic duct drainage with enteroscopy-assisted endoscopic retrograde pancreatography following Whipple surgery.

Our lab is focused on using comprehensive gene expression, methylation and sequencing and metabolomics analysis to identify alterations in breast cancer, and exploiting these for early detection and therapy. Among deferentially expressed genes, our lab has focused on the HOX genes. HOX genes are intimately involved in the development of resistance to both chemotherapy and to agents targeting the estrogen receptor. Our work explores the alternate pathways that are activated by HOX proteins leading to this resistance and novel treatments to overcome resistance in both tissue culture and xenograft models. In addition, epigenetically silenced genes and a metabolic reprogramming in tumors also trigger novel early detection and therapeutic strategies. We are testing the utility of differentiation therapy through reactivating RAR-beta in breast cancer using histone deacetylase inhibitors with great success. Also, we are targeting enzymes involved in gluconeogenesis and glycolysis with small molecule FDA-approved antimetabolites to achieve antitumor effects.